Stay updated on SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page.

Latest updates to the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page
- Check7 days agoChange DetectedAdded the MeSH term 'Cutaneous neuroendocrine carcinoma' and updated the page revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check49 days agoChange DetectedGastric cancer was added to the list of conditions for the study, broadening the potential population the page pertains to. A new Genetic and Rare Diseases Information Center resource was added under Resources, and the site revision banner updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check57 days agoChange DetectedRevision: v3.4.1 was added and v3.4.0 removed, indicating a version update that does not change study details or how the page is used.SummaryDifference0.0%

- Check79 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4, replacing the previous revision entry.SummaryDifference0.0%

- Check107 days agoChange DetectedA new consolidated Locations section lists participating sites across California, Colorado, Kentucky, Michigan, New York, Pennsylvania, South Dakota, Texas, and Utah, replacing the prior per-state headings. The footer revision note also updates from v3.3.2 to v3.3.3.SummaryDifference0.9%

Stay in the know with updates to SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page.